Physician profile
Aslam Ejaz
NPI 1275857120
$15,943.91
in general payments reported to CMS, 2019-2025
10 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.54 · 2023: $1,025 · 2024: $829 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,500.00 |
| Food and Beverage | $3,375.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $14,679.44 | 2023-2025 | Hemoblast Bellows |
| Boston Scientific Corporation | $424.22 | 2023 | Spyglass, Spyglass Discover, Axios |
| Medtronic, INC. | $202.26 | 2025 | Transorb, Signia |
| Histosonics, INC. | $149.44 | 2024 | |
| Intuitive Surgical, INC. | $144.87 | 2019-2023 | Da Vinci Surgical System |
| Tempus Ai, INC | $123.06 | 2024 | Xt Cdx |
| Intera Oncology, INC | $113.95 | 2024 | Intera |
| Medical Device Business Services, INC. | $76.83 | 2023 | |
| Beigene USA, INC. | $29.84 | 2025 | Brukinsa, Tevimbra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aslam Ejaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.